121 related articles for article (PubMed ID: 29427783)
1. Gout drugs use and risk of cancer: A case-control study.
Yang HC; Nguyen PAA; Islam M; Huang CW; Poly TN; Iqbal U; Li YJ
Joint Bone Spine; 2018 Dec; 85(6):747-753. PubMed ID: 29427783
[TBL] [Abstract][Full Text] [Related]
2. Allopurinol and the incidence of bladder cancer: a Taiwan national retrospective cohort study.
Chen CJ; Hsieh MC; Liao WT; Chan YT; Chang SJ
Eur J Cancer Prev; 2016 May; 25(3):216-23. PubMed ID: 25830898
[TBL] [Abstract][Full Text] [Related]
3. Association of gout medications and risk of cataract: a population-based case-control study.
Li YJ; Perng WT; Tseng KY; Wang YH; Wei JC
QJM; 2019 Nov; 112(11):841-846. PubMed ID: 31286139
[TBL] [Abstract][Full Text] [Related]
4. Increased risk of cancer among gout patients: a nationwide population study.
Kuo CF; Luo SF; See LC; Chou IJ; Fang YF; Yu KH
Joint Bone Spine; 2012 Jul; 79(4):375-8. PubMed ID: 22088929
[TBL] [Abstract][Full Text] [Related]
5. Risk of cutaneous adverse reactions associated with allopurinol or febuxostat in real-world patients: A nationwide study.
Lin CW; Huang WI; Chao PH; Chen WW; Hsiao FY
Int J Clin Pract; 2019 May; 73(5):e13316. PubMed ID: 30681751
[TBL] [Abstract][Full Text] [Related]
6. Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: a population-based study.
Shih HJ; Kao MC; Tsai PS; Fan YC; Huang CJ
Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):328-333. PubMed ID: 28398294
[TBL] [Abstract][Full Text] [Related]
7. Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan.
Yang CY; Chen CH; Deng ST; Huang CS; Lin YJ; Chen YJ; Wu CY; Hung SI; Chung WH
JAMA Intern Med; 2015 Sep; 175(9):1550-7. PubMed ID: 26193384
[TBL] [Abstract][Full Text] [Related]
8. Association of Chronic Kidney Disease With Allopurinol Use in Gout Treatment.
Vargas-Santos AB; Peloquin CE; Zhang Y; Neogi T
JAMA Intern Med; 2018 Nov; 178(11):1526-1533. PubMed ID: 30304329
[TBL] [Abstract][Full Text] [Related]
9. Gout can increase the risk of periodontal disease in Taiwan.
Chen HH; Ho CW; Hsieh MC; Chen CC; Hsu SP; Lin CL; Kao CH
Postgrad Med; 2020 Aug; 132(6):521-525. PubMed ID: 32298158
[No Abstract] [Full Text] [Related]
10. Adherence and persistence to urate-lowering therapies in the Irish setting.
McGowan B; Bennett K; Silke C; Whelan B
Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
[TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitor use associated with an increased risk of gout: A population-based case-control study.
Zhu KJ; Feng W; Ma XN; Liao PL; Lin CS; Huang JY; Wei JC; Xu Q
Int J Rheum Dis; 2023 Sep; 26(9):1799-1806. PubMed ID: 37470673
[TBL] [Abstract][Full Text] [Related]
12. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.
Stamp LK; Taylor WJ; Jones PB; Dockerty JL; Drake J; Frampton C; Dalbeth N
Arthritis Rheum; 2012 Aug; 64(8):2529-36. PubMed ID: 22488501
[TBL] [Abstract][Full Text] [Related]
13. Impact of allopurinol on risk of myocardial infarction.
Grimaldi-Bensouda L; Alpérovitch A; Aubrun E; Danchin N; Rossignol M; Abenhaim L; Richette P;
Ann Rheum Dis; 2015 May; 74(5):836-42. PubMed ID: 24395556
[TBL] [Abstract][Full Text] [Related]
14. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims.
Riedel AA; Nelson M; Joseph-Ridge N; Wallace K; MacDonald P; Becker M
J Rheumatol; 2004 Aug; 31(8):1575-81. PubMed ID: 15290738
[TBL] [Abstract][Full Text] [Related]
15. Nocturnal risk of gout attacks.
Choi HK; Niu J; Neogi T; Chen CA; Chaisson C; Hunter D; Zhang Y
Arthritis Rheumatol; 2015 Feb; 67(2):555-62. PubMed ID: 25504842
[TBL] [Abstract][Full Text] [Related]
16. Gout, allopurinol use, and heart failure outcomes.
Thanassoulis G; Brophy JM; Richard H; Pilote L
Arch Intern Med; 2010 Aug; 170(15):1358-64. PubMed ID: 20696962
[TBL] [Abstract][Full Text] [Related]
17. Incidence of Stevens-Johnson syndrome following combination drug use of allopurinol, carbamazepine and phenytoin in Taiwan: A case-control study.
Syu FK; Pan HY; Chuang PC; Huang YS; Cheng CY; Cheng FJ
J Dermatol; 2018 Sep; 45(9):1080-1087. PubMed ID: 29963717
[TBL] [Abstract][Full Text] [Related]
18. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.
Kim SC; Schneeweiss S; Choudhry N; Liu J; Glynn RJ; Solomon DH
Am J Med; 2015 Jun; 128(6):653.e7-653.e16. PubMed ID: 25660249
[TBL] [Abstract][Full Text] [Related]
19. Allopurinol adherence among patients with gout: an Italian general practice database study.
Mantarro S; Capogrosso-Sansone A; Tuccori M; Blandizzi C; Montagnani S; Convertino I; Antonioli L; Fornai M; Cricelli I; Pecchioli S; Cricelli C; Lapi F
Int J Clin Pract; 2015 Jul; 69(7):757-65. PubMed ID: 25683693
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the association between colchicine therapy and serious adverse events.
Todd BA; Billups SJ; Delate T; Canty KE; Kauffman AB; Rawlings JE; Wagner TM
Pharmacotherapy; 2012 Nov; 32(11):974-80. PubMed ID: 23019065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
